Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT00918983 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: NX-1207
DRUG: Placebo

Sponsor

Nymox Corporation